The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer

Published:2014-09-24 Issue:3 Volume:351 Page:538-548
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Coffey Greg,Betz Andreas,DeGuzman Francis,Pak Yvonne,Inagaki Mayuko,Baker Dale C.,Hollenbach Stanley J.,Pandey Anjali,Sinha Uma

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference62 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

2. SYK Is Upstream of Phosphoinositide 3-Kinase in B Cell Receptor Signaling

3. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

4. IFN‐α/β enhances BCR‐dependent B cell responses

5. Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL;Brown,2013

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications;Journal of Clinical Medicine;2024-08-20

2. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

3. Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics;MedComm – Oncology;2024-03

4. Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors;Haematologica;2024-01-18

5. Engineering cell-free systems by chemoproteomic-assisted phenotypic screening;RSC Chemical Biology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3